In recent years, tumor immunotherapy has made significant progress. However, tumor
immunotherapy, particularly immune checkpoint inhibitors (eg, PD-1/PD-L1 inhibitors) …

Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …

Cancer is now considered a tumor microenvironment (TME) disease, although it was
originally thought to be a cell and gene expression disorder. Over the past 20 years …

Immunotherapy has emerged as a breakthrough strategy in cancer treatment. mRNA
vaccines are an attractive and powerful immunotherapeutic platform against cancer because …

A therapeutic tumor vaccine is a promising approach to cancer treatment. One of its
strategies is to treat patient-derived tumor cells in vitro and then administer them in vivo to …

The critical challenge for cancer vaccine‐induced T‐cell immunity is the sustained activation
of antigen cross‐presentation in antigen‐presenting cells (APCs) with innate immune …

In recent years, there has been a surge of interest in tumor microenvironment-associated
cancer vaccine therapies. These innovative treatments aim to activate and enhance the …

Throughout the last decade, interventions to engineer the immune system called
immunotherapy have revolutionized the fields of oncology and autoimmune disease …

Microneedles are unique, novel and an effective approach designed to deliver therapeutic
agents and immunobiologicals in several diseases. These tiny needle patches are designed …

Background Increasing evidence suggests a correlation between glycosylation and the
onset of cancer. However, the clinical relevance of glycosylation-related genes (GRGs) in …